What matters
Key Takeaway
The Toronto-based fund is targeting a total of $125 million USD, signaling continued global interest in women’s and children’s health technologies.
Impacted Sectors
Operational lens: Women's and children's health technology investments
Next Steps / Actionable Advice
Check published results and source limitations before making a decision based on this announcement.
Cross-Border Impact Ventures (CBIV) has secured the first tranche of funding for its second investment vehicle, raising $58 million USD ($81 million CAD) to focus on improving health outcomes for women and children. The Toronto firm aims to raise a total of $125 million USD by the second half of 2027 through this new fund dedicated to Women’s and Children’s Health Technology.
The capital will be deployed into roughly a dozen companies across biotech, medical devices, and diagnostics, generally writing Series A and Series B cheques between $2 million and $5 million USD. CBIV maintains a global lens for its investments, requiring target companies to demonstrate both strong commercial potential and a clear line of sight toward regulatory approval.
The announcement highlights a significant operational tension: despite being based in Toronto, the fund has not yet invested in a Canadian company. The partners noted that finding deals at the early growth stages remains difficult due to what they described as a sparse medtech landscape for women’s health diagnostics and devices in Canada.
This local challenge occurs against a backdrop of declining funding activity; a recent report indicated life sciences saw a 39-percent year-over-year drop in funding activity in the Canadian venture capital sector. However, CBIV's continued fundraising efforts signal persistent international investor interest in impact-driven healthtech ventures, particularly those focused on gender and youth health.
The fund’s successful track record includes backing Sonio, a fetal ultrasound software company that was acquired by Samsung Medison for an estimated $92 million USD. The influx of capital from major limited partners like the German national development bank KfW underscores global confidence in dedicated impact funds, even as local Canadian early-stage medtech funding struggles to keep pace.
Sources & technical notes
Linked sourcesCheck the cited material to distinguish announcements from demonstrated results.
What to evaluate next
This box highlights the systems, workflows, and decisions the article helps you assess.
- For Canadian medtech startups to attract international growth capital, they must proactively demonstrate a robust commercialization path and address the perceived scarcity of deal flow at the early growth stage.
- Cross-Border Impact Ventures (CBIV) has secured the first tranche of funding for its second investment vehicle, raising $58 million USD ($81 million CAD) to focus on improving health outcomes for women and children.
- Operational lens: Women's and children's health technology investments